Last reviewed · How we verify
SHR1459 High Dose
At a glance
| Generic name | SHR1459 High Dose |
|---|---|
| Sponsor | Reistone Biopharma Company Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR1459 High Dose CI brief — competitive landscape report
- SHR1459 High Dose updates RSS · CI watch RSS
- Reistone Biopharma Company Limited portfolio CI